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Introduction
Familial Mediterranean fever disease (FMF) is an autoso-
mal recessively inherited disease characterized by recur-
rent, self-limited febrile episodes (attacks) with serositis,
synovitis, and occasionally skin involvement. The disease
primarily affects people of eastern Mediterranean des-
cent, typically presenting at age <20. AA amyloidosis is
the most serious complication of FMF and can be life-
threatening. Daily colchicine is considered standard of
care, and is expected to prevent attacks and amyloidosis
in most patients. Turkey has the highest prevalence with
0.1% in general population.
Objectives
This study aimed at exploring the potential number of
FMF patients with colchicine resistance in Turkey.
Methods
The study was based on expert opinions, as there is cur-
rently no defined diagnosis criteria or available data to
estimate the patient number. In the first stage of the study,
a questionnaire inquiring the type, frequency and duration
of the health care resources used for diagnosis and treat-
ment of the disease was prepared. Specific questions were
also asked about the epidemiology of the disease and col-
chicine resistant patients. Ten medical experts were
involved in the study. The questionnaire was e-mailed to
the experts and median numbers of their answers were
calculated. In the next stage, combined answers were dis-
cussed in a face-to-face meeting with the experts. All
items were discussed one by one until a consensus is
reached about the type, frequency and duration of health
care resources used during the diagnosis and treatment of
FMF patients.
Results
According to the expert views the prevalence of the dis-
ease is 0.1%. Among these patients, 65% are responders
to colchicine treatment, 30% are partial responders and
2-5% are colchicine resistant. Colchicine resistant FMF
(crFMF) patients are defined by consensus as patients
who have ≥ 1 attacks per month despite maximum toler-
able dose of colchicine treatment for 6 months period.
Conclusion
Since FMF is highly prevalent in Turkey, there is an
unmet need for CrFMF patients. It is estimated that
approximately 2.300 CrFMF patients are present in Tur-
key. This study has also shown that IL-1 agents are used
in treatment of CrFMF patients in Turkey.
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